T cell depletion utilizing the CliniMACS device will allow more precise, specific and controlled graft engineering of peripheral blood stem cells from unrelated and partially matched related donors without an increase in relapse or graft rejection and grade III or IV acute graft versus host disease (GVHD).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
Peripheral Blood Stem Cell Transplant
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
To measure the incidence and quality of engraftment
Time frame: Weekly for first 100 days, 6 months and 1 year
Evaluate the incidence of acute Graft versus Health Disease and treatment related mortality.
Time frame: weekly for the first 100 days and then 6 and 12 months post transplant date
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.